Anticancer agent 31_product_DataBase

Bioactivity	Anticancer agent 31 is a 1,3-diphenylurea quinoxaline derivative, and a anticancer agent. Anticancer agent 31 exhibits antitumor acitvity by arresting cell cycle at S phase and inducing apoptosis[1].
Invitro	Anticancer agent 31 (compound 2d) shows anticancer activity against human tumor cell lines (MGC-803, NCI-H460, T-24, HeLa, HepG2, and SMMC-7721) and displays lower cytotoxicity than 5-FU (HY-90006), Sorafenib (HY-10201), and Cisplatin (HY-17394)[1].Anticancer agent 31 (10, and 15 μM; 24 h) arrests cell cycle at S phase in MGC-803 cells, and induces tumor cells apoptosis[1].Anticancer agent 31 (5, 10, and 15 μM; 24 h) reduces cell cycle regulatory protein CDK2, CDK4, cyclin A2, cyclin B1, and Apaf-1, anti-apoptotic protein Bcl-2; increases pro-apoptotic protein Bax protein level[1].Anticancer agent 31 (5, 10 μM; 24 h) activates caspase-3 and caspase-9 by 73.6% and 65.3%, respectively; and also causes the loss of mitochondrial membrane potential (MMP) increase in JC-1 (HY-15534) detection[1]. Cell Cytotoxicity Assay[1] Cell Line:
Name	Anticancer agent 31
CAS	2222930-72-3
Formula	C28H21F2N5O2
Molar Mass	497.50
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Li GZ, et al. Synthesis and biological evaluation of novel 1,3-diphenylurea quinoxaline derivatives as potent anticancer agents. Med Chem Res 30,2021. 1496-1511.

PeptideDB